Investor Moves
| Investor | Portfolio Value | Portfolio Change | Position Change | Avg Buy Price | Current Price |
|---|---|---|---|---|---|
Jim SimonsRenaissance Technologies $-63.5K ExitQ4 2025 $64k -- -- | |||||
Ken GriffinCitadel Advisors $-111.7K ExitQ1 2025 $112k -- -- | |||||
Jim SimonsRenaissance Technologies $-52.2K ExitQ1 2025 $52k -- -- | |||||
Ken GriffinCitadel Advisors $-16.1K ExitQ3 2024 $16k -- -- | |||||
News
accessnewswire.comMIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1accessnewswire.comJun 4
accessnewswire.comMIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPNaccessnewswire.comMay 27
accessnewswire.comMIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2accessnewswire.comMay 14
accessnewswire.comMIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidateaccessnewswire.comMay 13
newsfilecorp.comVisionstate Reports 27% Q2 Revenue Growth as MIRA Platform Gains Tractionnewsfilecorp.comMay 6